Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety. AARD-001 remains under clinical development and is not an approved commercial product.

Aardvark Therapeutics primarily operates in the United States and has not reported a broad portfolio of marketed medicines. The company’s current activities are centered on advancing its obesity-focused pipeline through clinical development and evaluation.

Key Stats

• Today's Range: $3.77 to $3.98
• 50-Day Range: $3.86 to $7.90
• 52-Week Range: $3.35 to $16.60
• Volume: 68,796 shs
• Average Volume: 128,696 shs
• Market Capitalization: $84.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.13
• Consensus Rating: Hold

Aardvark Therapeutics Stock Analysis - MarketRank™

Aardvark Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 311th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Aardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 1 strong buy rating, 4 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Aardvark Therapeutics has a consensus price target of $13.13, representing about 240.0% upside from its current price of $3.86.

Amount of Analyst Coverage

Aardvark Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.17) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aardvark Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aardvark Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aardvark Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.64% of the float of Aardvark Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aardvark Therapeutics has a short interest ratio ("days to cover") of 5.29.

Change versus previous month

Short interest in Aardvark Therapeutics has recently increased by 11.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aardvark Therapeutics does not currently pay a dividend.

Dividend Growth

Aardvark Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.22

News Sentiment

Aardvark Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Aardvark Therapeutics this week, compared to 8 articles on an average week.

MarketBeat Follows

3 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aardvark Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394,930.00 in company stock.

Percentage Held by Insiders

17.80% of the stock of Aardvark Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Aardvark Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: aardvarktherapeutics.com
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 28
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $13.13
• High Price Target: $47.00
• Low Price Target: $3.00
• Potential Upside/Downside: +240.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.54%
• Return on Assets: -64.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.63
• Quick Ratio: 12.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.90 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 21,884,000
• Free Float: 17,989,000
• Market Cap: $84.47 million
• Optionable: N/A
• Beta: 3.80